SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER

孢子：胃肠癌中的 DF/HCC 孢子

• 批准号: 8472972
• 负责人: CHARLES S FUCHS
• 金额: $ 215.05万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-31 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8472972
• 关键词: Address; BRAF gene; Basic Science; Bioinformatics; Biological; Biometry; Boston; Cancer Biology; Cancer Center; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Colorectal; Colorectal Cancer; Communication; Dana-Farber Cancer Institute; Databases; Detection; Development; Diagnosis; Diagnostic; Dysplasia; Dysplasia in Barrett' s Esophagus; Early Diagnosis; Evaluation; Funding; General Hospitals; Genetic; Genomics; Goals; Hospitals; Imaging technology; Institutes; Institution; Investigation; Israel; KRAS2 gene; Knowledge; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Massachusetts; Medical center; Mentors; Modeling; Mutation; Outcome; PDGFRA gene; Pathology; Patients; Pediatric Hospitals; Population; Population Sciences; Prevention; Public Health Schools; Recording of previous events; Regimen; Reporting; Research Personnel; Resistance; Resources; Role; Scientist; Signal Pathway; Specialized Program of Research Excellence; Specimen; Technology; Therapeutic; Time; Tissues; Translating; Translational Research; Translations; Vitamin D; Woman; Work; anticancer research; base; cancer prevention; cancer therapy; carcinogenesis; career development; clinical decision-making; clinically relevant; design; effective therapy; flexibility; gastrointestinal; improved; innovation; kinase inhibitor; medical schools; molecular imaging; mutant; novel; novel therapeutic intervention; novel therapeutics; patient population; prevent; prognostic; programs; public health relevance; repository; research and development; resistance mechanism; response; success; tool; translational study; tumor progression

DESCRIPTION (provided by applicant): This application represents the competitive renewal of a Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer originating from the Gastrointestinal (GI) Malignancies Program of the Dana-Farber/Harvard Cancer Center (DF/HCC). The main goal of the DF/HCC SPORE in GI Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of gastrointestinal malignancies. The DF/HCC SPORE in GI Cancer includes researchers from all Harvard-affiliated hospitals and institutions: the Dana-Farber Cancer Institute, the Brigham and Women's Hospital, the Massachusetts General Hospital, the Beth Israel Deaconess Medical Center, Children's Hospital of Boston, Harvard Medical School, Harvard School of Public Health, and Broad Institute. Five major projects are proposed including: 1) Molecular imaging for detection of high grade dysplasia in Barrett's Esophagus; 2) Defining the role of vitamin D in colorectal carcinogenesis and cancer survival; 3) Identifying novel therapeutic strategies for KRAS-mutant colorectal cancer; 4) Overcoming resistance to RAF inhibition in BRAF-mutant colorectal cancer; and 5) Overcoming Resistance to KIT/PDGFRA Inhibition in GIST. These projects will be integrated by three cores: 1) Administration, Evaluation & Planning; 2) Tissue & Pathology; and 3) Biostatistics & Bioinformatics. The SPORE application outlines a Developmental Projects Program that includes a plan of selection of new projects and documents 18 highly innovative and productive developmental projects that have been supported during the current funding cycle. We also include a Career Development Program that outlines a mechanism for the identification and support of talented young investigators in GI cancer and report on our success in supporting and mentoring 15 young investigators during the current funding cycle. The projects and cores proposed in this application are highly integrated with present DF/HCC core resources, and involve key collaborations with investigators from other existing SPOREs and cancer centers. The renewal of this GI SPORE at DF/HCC will combine leading Harvard researchers in basic, translational, and clinical sciences into a program that has the focus and coordination required to produce meaningful advances in the diagnosis, treatment, and prevention of GI cancers.

描述（由申请人提供）：本申请代表了源自Dana-Farber/哈佛癌症中心（DF/HCC）胃肠道（GI）肿瘤项目的胃肠道癌症卓越研究专业项目（SPORE）的竞争性更新。DF/HCC SPORE在GI癌症中的主要目标是将生物学和技术进步转化为预防，诊断，结局预测因子的改进以及胃肠道恶性肿瘤治疗的进展。胃肠道癌症DF/HCC SPORE包括来自所有哈佛附属医院和机构的研究人员：Dana-Farber癌症研究所，Brigham和妇女医院，马萨诸塞州总医院，Beth Israel Deaconess医疗中心，波士顿儿童医院，哈佛医学院，哈佛公共卫生学院和布罗德研究所。提出了五个主要项目，包括：1）用于检测Barrett食管高度异型增生的分子成像; 2）确定维生素D在结直肠癌发生和癌症存活中的作用; 3）确定KRAS突变结直肠癌的新治疗策略; 4）克服BRAF突变结直肠癌中RAF抑制的抗性;和5）克服GIST中KIT/PDGFRA抑制的抗性。这些项目将由三个核心整合：1）管理，评估和规划; 2）组织和病理学; 3）生物统计学和生物信息学。SPORE申请概述了一个发展项目计划，其中包括一个新项目的选择计划，并记录了18个在当前资助周期内获得支持的高度创新和富有成效的发展项目。我们还包括一个职业发展计划，概述了一个机制，以识别和支持有才华的年轻研究人员在胃肠道癌症和报告我们成功地支持和指导15个年轻的研究人员在当前的资金周期。本申请中提出的项目和核心与目前的DF/HCC核心资源高度整合，并涉及与其他现有SPORE和癌症中心的研究者的关键合作。DF/HCC的GI孢子更新将联合收割机结合哈佛基础、转化和临床科学领域的领先研究人员，形成一个项目，该项目具有在GI癌症的诊断、治疗和预防方面取得有意义进展所需的重点和协调。